前列腺癌体系突变及治疗研究进展

吴礼益; 严维刚

doi:10.12290/xhyxzz.2022-0717

前列腺癌体系突变及治疗研究进展

doi: 10.12290/xhyxzz.2022-0717

吴礼益,
严维刚^,

中国医学科学院北京协和医院泌尿外科，北京 100730

基金项目:

中央高水平医院临床科研专项 2022-PUMCH-A-063

详细信息

通讯作者:
严维刚, E-mail: ywgpumch@sina.com

中图分类号: R737.25; Q344+.12
计量
- 文章访问数: 185
- HTML全文浏览量: 41
- PDF下载量: 28
- 被引次数: 0
出版历程
- 收稿日期: 2022-12-19
- 录用日期: 2023-01-31
- 刊出日期: 2023-07-30

Research Progress of Prostate Cancer Somatic Mutation and Treatment

WU Liyi,
YAN Weigang^,

Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

National High Level Hospital Clinical Research Funding 2022-PUMCH-A-063

More Information

Corresponding author: YAN Weigang, E-mail: ywgpumch@sina.com

摘要

摘要: 前列腺癌是目前全球最常见的男性恶性肿瘤之一，严重威胁中老年男性健康。前列腺癌患者的临床表现和疾病预后具有个体差异，低危患者病程缓慢，死亡风险较低，而中高危患者预后较差，死亡风险较高。目前研究表明，前列腺癌的临床表现与基因突变相关，而体系突变作为前列腺癌基因突变的重要组成部分，与肿瘤的发生转移相关，可作为前列腺癌患者危险分级预后预测的潜在依据。本文就前列腺癌体系突变及治疗研究进展作一综述，以期为该疾病的诊断治疗提供借鉴。
- 前列腺癌 /
- 体系突变 /
- 研究进展 /
- 诊疗价值
Abstract: Prostate cancer, one of the most common male malignancies in the world, seriously threatens the health of middle-aged and elderly men. The clinical manifestations and prognosis of prostate cancer patients have individual differences. Most low-risk patients have a slow disease course and a low risk of death, while intermediate- and high-risk patients have a poor prognosis and a high risk of death. Current studies have shown that prostate cancer genes have complex genetic heterogeneity associated with clinical manifestations and somatic mutation is an important part of prostate cancer genome variations. With the development of high-throughput sequencing technology, related research is increasing. This article reviews the research progress on somatic mutations in prostate cancer and treatment to provide reference for prognosis prediction and drug treatment of the disease.
- prostate cancer /
- somatic mutation /
- research progress /
- diagnostic and therapeutic value
注释:

作者贡献：吴礼益负责文献整理与论文撰写；严维刚负责论文修订及审校。

利益冲突：所有作者均声明不存在利益冲突

HTML全文

参考文献(35)

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. doi: 10.3322/caac.21660
[2]	Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part Ⅰ: Introduction, Risk Assessment, Staging, and Risk-Based Management[J]. J Urol, 2022, 208: 10-18. doi: 10.1097/JU.0000000000002757
[3]	Haffner MC, Zwart W, Roudier MP, et al. Genomic and phenotypic heterogeneity in prostate cancer[J]. Nat Rev Urol, 2021, 18: 79-92. doi: 10.1038/s41585-020-00400-w
[4]	Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion[J]. Am J Surg Pathol, 2007, 31: 882-888. doi: 10.1097/01.pas.0000213424.38503.aa
[5]	Zhu Y, Mo M, Wei Y, et al. Epidemiology and genomics of prostate cancer in Asian men[J]. Nat Rev Urol, 2021, 18: 282-301. doi: 10.1038/s41585-021-00442-8
[6]	Kaffenberger SD, Barbieri CE. Molecular subtyping of prostate cancer[J]. Curr Opin Urol, 2016, 26: 213-218. doi: 10.1097/MOU.0000000000000285
[7]	Abeshouse A, Ahn J, Akbani R, et al. The molecular taxonomy of primary prostate cancer[J]. Cell, 2015, 163: 1011-1025. doi: 10.1016/j.cell.2015.10.025
[8]	Stopsack KH, Nandakumar S, Wibmer AG, et al. Onco-genic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer[J]. Clin Cancer Res, 2020, 26: 3230-3238. doi: 10.1158/1078-0432.CCR-20-0168
[9]	Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location[J]. Am J Mens Health, 2018, 12: 1807-1823. doi: 10.1177/1557988318798279
[10]	Stopsack KH, Nandakumar S, Arora K, et al. Differences in Prostate Cancer Genomes by Self-Reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical FactorsRacial Differences in Prostate Cancer Genomes[J]. Clin Cancer Res, 2022, 28: 318-326. doi: 10.1158/1078-0432.CCR-21-2577
[11]	Li J, Xu C, Lee HJ, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations[J]. Nature, 2020, 580: 93-99. doi: 10.1038/s41586-020-2135-x
[12]	Grossmann S, Hooks Y, Wilson L, et al. Development, maturation, and maintenance of human prostate inferred from somatic mutations[J]. Cell Stem Cell, 2021, 28: 1262-1274. doi: 10.1016/j.stem.2021.02.005
[13]	Stjohn J, Powell K, Conley-Lacomb MK, et al. TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression[J]. J Cancer Sci Ther, 2012, 4: 94-101.
[14]	Zhou F, Gao S, Han D, et al. TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells[J]. Oncogene, 2019, 38: 4397-4411. doi: 10.1038/s41388-019-0730-9
[15]	Hong Z, Zhang W, Ding D, et al. DNA damage promotes TMPRSS2-ERG oncoprotein destruction and prostate cancer suppression via signaling converged by GSK3β and WEE1[J]. Mol Cell, 2020, 79: 1008-1023. doi: 10.1016/j.molcel.2020.07.028
[16]	Shoag J, Liu D, Blattner M, et al. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG[J]. J Clin Invest, 2018, 128: 381-386.
[17]	Bernasocchi T, El Tekle G, Bolis M, et al. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer[J]. Nat Commun, 2021, 12: 1-18. doi: 10.1038/s41467-020-20314-w
[18]	Zhang J, Chen M, Zhu Y, et al. SPOP promotes nanog destruction to suppress stem cell traits and prostate cancer progression[J]. Dev Cell, 2019, 48: 329-344. doi: 10.1016/j.devcel.2018.11.035
[19]	Luo Z, Wang J, Zhu Y, et al. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway[J]. Neoplasia, 2021, 23: 1037-1047. doi: 10.1016/j.neo.2021.08.002
[20]	Teng M, Zhou S, Cai C, et al. Pioneer of prostate cancer: past, present and the future of FOXA1[J]. Protein Cell, 2021, 12: 29-38. doi: 10.1007/s13238-020-00786-8
[21]	Gao S, Chen S, Han D, et al. Forkhead domain mutations in FOXA1 drive prostate cancer progression[J]. Cell Res, 2019, 29: 770-772. doi: 10.1038/s41422-019-0203-2
[22]	Song B, Park SH, Zhao JC, et al. Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression[J]. J Clin Invest, 2019, 129: 569-582.
[23]	Zhou S, Hawley J, Soares F, et al. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer[J]. Nat Commun, 2020, 11: 441. doi: 10.1038/s41467-020-14318-9
[24]	Aurilio G, Cimadamore A, Mazzucchelli R, et al. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications[J]. Cells, 2020, 9: 2653. doi: 10.3390/cells9122653
[25]	Li Y, Yang R, Henzler CM, et al. Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate CancerAR Gene Rearrangements in Prostate Cancer[J]. Clin Cancer Res, 2020, 26: 1965-1976. doi: 10.1158/1078-0432.CCR-19-3023
[26]	Zhu Y, Dalrymple SL, Coleman I, et al. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors[J]. Oncogene, 2020, 39: 6935-6949. doi: 10.1038/s41388-020-01479-6
[27]	Zhou T, Wang S, Song X, et al. RNF8 up-regulates AR/ARV7 action to contribute to advanced prostate cancer progression[J]. Cell Death Dis, 2022, 13: 1-15.
[28]	Donehower LA, Soussi T, Korkut A, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas[J]. Cell Rep, 2019, 28: 1370-1384. doi: 10.1016/j.celrep.2019.07.001
[29]	Nientiedt C, Budczies J, Endris V, et al. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer[J]. Urol Oncol, 2022, 40: 8. e11-8. e18.
[30]	Hamid A, Gray P, Shaw G, et al. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer[J]. Eur Urol, 2019, 76: 89-97. doi: 10.1016/j.eururo.2018.11.045
[31]	LIU Z, GUO H, ZHU Y, et al. TP53 alterations of hormone-naive prostate cancer in the Chinese population[J]. Prostate Cancer Prostatic Dis, 2021, 24: 482-491. doi: 10.1038/s41391-020-00302-3
[32]	Annala M, Vandekerkhove G, Khalaf D, et al. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerctDNA and Resistance to AR-Targeted Therapy[J]. Cancer Discov, 2018, 8: 444-457. doi: 10.1158/2159-8290.CD-17-0937
[33]	Rampias T, Karagiannis D, Avgeris M, et al. The lysine specific methyltransferase KMT 2C/MLL 3 regulates DNA repair components in cancer[J]. EMBO Rep, 2019, 20: e46821. doi: 10.15252/embr.201846821
[34]	Wei Y, Wu J, Gu W, et al. Germline DNA repair gene mutation landscape in Chinese prostate cancer patients[J]. Eur Urol, 2019, 76: 280-283. doi: 10.1016/j.eururo.2019.06.004
[35]	Messina C, Cattrini C, Soldato D, et al. BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications[J]. J Oncol, 2020, 2020: 4986365.

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 185
HTML全文浏览量: 41
PDF下载量: 28
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

前列腺癌体系突变及治疗研究进展

doi: 10.12290/xhyxzz.2022-0717

通讯作者:
严维刚, E-mail: ywgpumch@sina.com

计量

Research Progress of Prostate Cancer Somatic Mutation and Treatment

Corresponding author: YAN Weigang, E-mail: ywgpumch@sina.com

计量

目录

留言板

前列腺癌体系突变及治疗研究进展

doi: 10.12290/xhyxzz.2022-0717

通讯作者: 严维刚, E-mail: ywgpumch@sina.com

计量

出版历程

Research Progress of Prostate Cancer Somatic Mutation and Treatment

Corresponding author: YAN Weigang, E-mail: ywgpumch@sina.com

计量

出版历程

目录

通讯作者:
严维刚, E-mail: ywgpumch@sina.com